Nucleoside analogue reverse transcriptase inhibitors differentially inhibit human LINE-1 retrotransposition

77Citations
Citations of this article
113Readers
Mendeley users who have this article in their library.

Abstract

Background: Intact LINE-1 elements are the only retrotransposons encoded by the human genome known to the capable of autonomous replication. Numerous cases of genetic disease have been traced to gene disruptions caused by LINE-1 retrotransposition events in germ-line cells. In addition, genomic instability resulting from LINE-1 retrotransposition in somatic cells has been proposed as a contributing factor to oncogenesis and to cancer progression. LINE-1 element activity may also play a role in normal physiology. Methods and Principal Findings: Using an in vitro LINE-1 retrotransposition reporter assay, we evaluated the abilities of several antiretroviral compounds to inhibit LINE-1 retrotransposition. The nucleoside analogue reverse transcriptase inhibitors (nRTIs): stavudine, zidovudine, tenofovir disoproxil fumarate, and lamivudine all inhibited LINE-1 retrotransposition with varying degrees of potencies, while the non-nucleaside HIV-1 reverse transcriptase inhibitor nevirapine showed no effect. Conclusions/Significance: Our data demonstrates the ability for nRTIs to suppress LINE-1 retrotransposition. This is immediately applicable to studies aimed at examining potential roles for LINE-1 retrotransposition in physiological processes involving LINE-1 retrotransposition. © 2008 Jones et al.

Cite

CITATION STYLE

APA

Jones, R. B., Garrison, K. E., Wong, J. C., Duan, E. H., Nixon, D. F., & Ostrowski, M. A. (2008). Nucleoside analogue reverse transcriptase inhibitors differentially inhibit human LINE-1 retrotransposition. PLoS ONE, 3(2). https://doi.org/10.1371/journal.pone.0001547

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free